Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Why Lake Resources, Pro Medicus, Race Oncology, and Universal Store shares are rising today
This ASX All Ords biotech share is on a 16% tear today
Guess which ASX All Ords share is soaring 12% on a 'key step'
2 ASX healthcare shares racing higher on positive updates
Why Allkem, IGO, Northern Star, and Race Oncology shares are racing higher
Why Aeris Resources, Evolution, Li-S Energy, and Race Oncology shares are charging higher
4 ASX All Ords shares smashing the market on big news
Why Block, Mincor, Race Oncology, and Weebit Nano shares are sinking today
Why is ASX All Ords healthcare share Race Oncology plummeting 10% today?
Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher
Share Market News
4 ASX All Ords shares insiders have been buying up in January
Share Market News
This ASX All Ords director has bought 25,000 of his company's shares in a week
No, Race Oncology does not pay dividends at this time.
Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.
Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.
The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).
As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.
|01 Dec 2023||$0.85||$-0.01||-1.17%||84,183||$0.84||$0.85||$0.81|
|30 Nov 2023||$0.86||$-0.06||-6.59%||252,304||$0.88||$0.90||$0.81|
|29 Nov 2023||$0.91||$0.04||4.62%||108,562||$0.85||$0.91||$0.85|
|28 Nov 2023||$0.87||$-0.03||-3.35%||147,314||$0.90||$0.90||$0.83|
|27 Nov 2023||$0.90||$-0.02||-2.18%||108,421||$0.92||$0.92||$0.86|
|24 Nov 2023||$0.92||$0.04||4.57%||410,485||$0.93||$0.93||$0.84|
|23 Nov 2023||$0.88||$0.01||1.15%||368,599||$0.90||$0.95||$0.82|
|22 Nov 2023||$0.87||$-0.04||-4.40%||1,050,985||$0.95||$1.00||$0.87|
|21 Nov 2023||$0.91||$0.00||0.00%||15,768||$0.93||$0.94||$0.91|
|20 Nov 2023||$0.91||$-0.03||-3.18%||24,350||$0.94||$0.94||$0.88|
|17 Nov 2023||$0.94||$0.01||1.07%||62,900||$0.93||$0.94||$0.87|
|16 Nov 2023||$0.93||$0.01||1.08%||19,307||$0.92||$0.93||$0.90|
|15 Nov 2023||$0.92||$0.02||2.21%||109,345||$0.91||$0.95||$0.91|
|14 Nov 2023||$0.90||$-0.02||-2.16%||91,165||$0.92||$0.93||$0.89|
|13 Nov 2023||$0.92||$0.04||4.52%||131,690||$0.91||$0.92||$0.84|
|10 Nov 2023||$0.89||$-0.03||-3.26%||165,701||$0.92||$0.93||$0.85|
|09 Nov 2023||$0.92||$-0.08||-8.00%||313,087||$1.03||$1.03||$0.92|
|08 Nov 2023||$1.00||$0.03||3.10%||617,859||$0.97||$1.07||$0.95|
|07 Nov 2023||$0.97||$0.10||11.48%||821,429||$0.97||$1.01||$0.93|
|03 Mar 2023||Mary Harney||Issued||110,392||$250,589||
Issue of options.
|03 Mar 2023||Daniel Sharp||Issued||110,392||$250,589||
Issue of options.
|03 Mar 2023||Damian Clarke Bruce||Issued||755,671||$1,715,373||
Issue of options.
|07 Feb 2023||Daniel Tillett||Buy||6,793||$13,044||
|13 Jan 2023||Daniel Tillett||Buy||25,550||$50,223||
On-market trade. There is reporting error in the announcement for value, hence value has been updated according to price history. Considering 1.9656 per share value.
|20 Dec 2022||Daniel Tillett||Buy||46,737||$99,198||
|Mr Phillip(Phil) R Lynch||Non-Executive Director||Feb 2023||
Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an experienced executive and board director, with a background across corporate development, strategy, financial performance, marketing and governance.
|Ms Mary Harney||Non-Executive Director||Feb 2021||
Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company.
|Dr Peter (Pete) Smith||Executive Director||Jun 2023||
Dr Smith has over 30 years of experience in the pharmaceutical and biotech industry, in therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private biotechnology company Myrio Therapeutics. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A. His undergraduate degree and PhD are from the University of Cambridge. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.
|Mr Peter Webse||Company Secretary||Aug 2016||
|Peter Webse||Company Secretary||
|Dr Daniel Tillett||14,014,370||8.59%|
|Mr Phillip Richard Perry||6,047,694||3.71%|
|Mr Mark Phillip Juan||5,652,312||3.47%|
|Biosynergy Partners Pty Ltd||5,102,194||3.13%|
|The Trust Company (Australia) Limited <MOF A/C>||4,450,468||2.73%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||2,648,807||1.62%|
|Dr Daniel Tillett (ii)||2,307,925||1.42%|
|Craganorig Holdings LLC||2,000,000||1.23%|
|Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C>||1,600,000||0.98%|
|Mr Anthony James Robinson <The Peeko Family No 86 A/C>||1,579,250||0.97%|
|Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C>||1,350,000||0.83%|
|Kudoss Investments Pty Ltd <Aitken Global Family A/C>||1,153,034||0.71%|
|Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C>||1,080,000||0.66%|
|Mr Sandor Helby||1,060,000||0.65%|
|Mr Alan Giles Sauran||1,031,256||0.63%|
|Biosynergy Partners Pty Ltd (ii)||1,000,000||0.61%|
|Citicorp Nominees Pty Limited||856,443||0.53%|
|Mr Van Quy Do||825,788||0.51%|
|Mr Brian James Walker||777,777||0.48%|